MCM
TELO icon

Morton Capital Management’s Telomir Pharmaceuticals TELO Stock Holding History

Morton Capital Management’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.5K Hold
12,658
– – ﹤0.01% 138
2025
Q4 		$16.8K Buy
+12,658
New +$18.3K ﹤0.01% 134

Other funds holding TELO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Morton Capital Management's TELO Position: Q1 2026 in Review

Morton Capital Management held its Telomir Pharmaceuticals (TELO) position steady in Q1 2026 at 12,658 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #138.

Morton Capital Management first reported a position in TELO in Q4 2025 and has held it in 2 quarters since. The position peaked at $16.8K in Q4 2025. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

  • Morton Capital Management held 12,658 shares of Telomir Pharmaceuticals worth $16.5K as of Q1 2026.
  • Morton Capital Management left its Telomir Pharmaceuticals share count unchanged in Q1 2026.
  • Telomir Pharmaceuticals made up ﹤0.01% of Morton Capital Management's portfolio in Q1 2026, its #138 holding.
  • Morton Capital Management first reported a position in Telomir Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Morton Capital Management's Telomir Pharmaceuticals position peaked at $16.8K in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on Morton Capital Management's 13F filing for Q1 2026, filed 21 Apr 2026.